Sep 21, 2026
Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
Clene Inc. has closed a $4 million registered direct offering, with investments led by its Chairman, founding investor Kensington Capital Holdings, and the CEO. This funding is expected to extend the company's capital runway until mid-first quarter 2027, which is beyond the potential FDA decision on its CNM-Au8® NDA for ALS. Additionally, if the NDA is accepted, Clene could receive an extra $6.7 million to $7.8 million from warrants, further bolstering its cash position.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
Sep 16, 2026
Clene Announces $4 Million Registered Direct Offering
Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company, announced a $4 million registered direct offering of 1,219,513 shares at $3.28 per share to existing shareholders, including insiders. The offering, led by Clene's Chairman and founding investor Kensington Capital Holdings, is expected to close on September 17, 2026. The proceeds are intended to fund the company's operations until mid-first quarter 2027 and support regulatory efforts for its drug candidate CNM-Au8.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish